Analysis of the IL-6-mediated intracellular signaling molecules in myeloma cell growth

骨髓瘤细胞生长中 IL-6 介导的细胞内信号分子分析

基本信息

  • 批准号:
    17590999
  • 负责人:
  • 金额:
    $ 2.24万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    2005
  • 资助国家:
    日本
  • 起止时间:
    2005 至 2006
  • 项目状态:
    已结题

项目摘要

A cytokine, interleukin-6 (IL-6) is a growth factor for human myeloma cells. Upon IL-6 stimulation, signal transducer and activator of transcription (STAT) 3 and extracellular signal-regulated kinase (ERK) 1/2 are activated. We recently found that in myeloma cell lines the activation of both STAT3 and ERK1/2 is not sufficient for the IL-6-induced proliferation, which further requires the activation of the src family protein-tyrosine kinases (PTKs), such as Lyn, associated with the CD45 protein-tyrosine phosphatase (PTP). To explore the molecular mechanism that governs how IL-6 stimulation induces the proliferation of myeloma cells, such as downstream molecules of Lyn, we have established the myeloma cell lines, ILKM2 and ILKM8 overexpressing Lyn. We have found that both the Lyn-overexpressed ILKM2 and ILKM8 have the higher proliferative rate in response to IL-6 than that of their mock counterpart. In contrast, in the absence of IL-6 these Lyn-overexpressed cell lines showed higher susc … More eptibility to cell death. Cell surface expression of IL-6 receptor a and CD45 was not influenced by the Lyn-overexpression. We have also found that the enhanced activation of the phosphatidylinositol 3-kinase (PI3-K) and Akt in the Lyn-overexpressed cells with IL-6, whereas the activation levels of two other major IL-6-responsive molecules, STAT3 and ERK1/2 remained unchanged, indicating that these are the independent signaling pathways of the Lyn-PI3K-Akt. In the Lyn-overexpressed cells, the Lyn PTK seems to be constitutively active because the positive regulatory tyrosine residue in the catalytic domain was highly phosphorylated, while the negative regulatory tyrosine residue in the COOH-terminus was not phosphorylated, presumably due to its dephosphorylation by CD45 PTP. The PI3-K was co-precipitated with Lyn in the immunoprecipitation assay, and specific inhibition of PI3-K or Akt activities by the pharmacologic reagents suppressed the IL-6-induced proliferation of the Lyn-overexpressed cells, suggesting that the activation of the PI3K-Akt pathways associated with the activated Lyn is indeed related to their concomitant augmentation of myeloma cell growth although the downstream signaling molecules are still need to be explicated. Experiments are also underway to clarify the possible mechanisms of the accelerated cell death of the Lyn-overexpressed myeloma cells as a consequence of the IL-6 withdrawal, our work will provide an understanding of Lyn's role in the IL-6 receptor-mediated signaling. Less
细胞因子白细胞介素6(IL-6)是人骨髓瘤细胞的生长因子。在IL-6刺激下,转录3(Stat)3和细胞外信号调节激酶(ERK)1/2的活化剂被激活。我们最近发现,在骨髓瘤细胞系中,STAT3和ERK1/2的激活对于IL-6诱导的增殖不足,这进一步需要激活SRC家族蛋白蛋白 - 酪氨酸激酶(PTK),例如Lyn,例如与CD45蛋白质蛋白质蛋白质蛋白质 - 磷酸糖苷磷酸酶(PTP)相关的LYN。为了探索控制IL-6如何刺激骨髓瘤细胞增殖的分子机制,例如Lyn的下游分子,我们已经建立了骨髓瘤细胞系,ILKM2和ILKM8过表达Lyn。我们发现,响应于IL-6的Lyn越过表达的ILKM2和ILKM8都比其模拟对应物具有更高的增殖率。相比之下,在没有IL-6的情况下,这些lyn倒闭的细胞系显示了更高的SUSC……对细胞死亡的可疑性。 IL-6受体A和CD45的细胞表面表达不受Lyn-Over表达的影响。 We have also found that the enhanced activation of the phosphatidylinositol 3-kinase (PI3-K) and Akt in the Lyn-overexpressed cells with IL-6, whereas the activation levels of two Other major IL-6-responsive molecules, STAT3 and ERK1/2 remained unchanged, indicating that these are the independent signaling pathways of the Lyn-PI3K-Akt.在LYN过表达的细胞中,Lyn PTK似乎一直保持活跃,因为催化结构域中的阳性调节酪氨酸在催化结构域中的阳性保留率高度磷酸化,而COOH-Terminus中的负调节酪氨酸在COOH-terminus中的负磷酸含量并未磷酸化,这可能是由于其由CD45 ptp的Dephosphoryation而导致的。 The PI3-K was co-precipitated with Lyn in the immunoprecipitation assay, and specific inhibition of PI3-K or Akt activities by the pharmaceutical reagents suppressed the IL-6-induced proliferation of the Lyn-overexpressed cells, suggesting that the activation of the PI3K-Akt pathways associated with the activated Lyn is indeed related to their concomitant augmentation of myeloma cell growth although仍然需要明确的下游信号分子。实验也正在进行中,以阐明由于IL-6戒断而导致LYN表达的骨髓瘤细胞加速细胞死亡的可能机制,我们的工作将提供对Lyn在IL-6受体介导的信号传导中的作用的理解。较少的

项目成果

期刊论文数量(13)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
A rapid translocation of CD45RO but not CD45RA to lipid rafts in IL-6-induced proliferation in myeloma
IL-6诱导的骨髓瘤增殖中CD45RO而非CD45RA快速易位至脂筏
  • DOI:
  • 发表时间:
    2005
  • 期刊:
  • 影响因子:
    0
  • 作者:
    山崎雅英;舟田久;Fu-Jun Li
  • 通讯作者:
    Fu-Jun Li
Baicalein, a component of Scutellaria radix from Huang-Liang-Jie-Du-Tang (HLJDT), leads to suppression of proliferation and induction of apoptosis in human myeloma cells
黄芩素是黄芪解毒汤 (HLJDT) 中的一种成分,可抑制人骨髓瘤细胞的增殖并诱导细胞凋亡
  • DOI:
  • 发表时间:
    2005
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Kato-J;Kobune-M;Zi Ma
  • 通讯作者:
    Zi Ma
Mitogenic signals initiated via IL-6 receptor complexes in cooperation with other transmembrane molecules in myelomas
通过 IL-6 受体复合物与骨髓瘤中其他跨膜分子合作启动有丝分裂信号
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ISHIKAWA Hideaki其他文献

ISHIKAWA Hideaki的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ISHIKAWA Hideaki', 18)}}的其他基金

Development and the utilization of the social science education unification program to promote new combination of the knowledge
社会科学教育统一方案的开发与运用促进知识新结合
  • 批准号:
    24650534
  • 财政年份:
    2012
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
The Role of the Lyn-PI 3-kinase signaling pathways and PKM2 in the myeloma cell proliferation
Lyn-PI 3激酶信号通路和PKM2在骨髓瘤细胞增殖中的作用
  • 批准号:
    22591039
  • 财政年份:
    2010
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The origin of analytic properties of zeta functions on the domain where they are divergent
Zeta 函数在其发散域上的分析性质的起源
  • 批准号:
    22740019
  • 财政年份:
    2010
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Analysis of the CD45-Lyn-mediated signaling pathways in theIL-6-induced myeloma cell proliferation
IL-6诱导骨髓瘤细胞增殖中CD45-Lyn介导的信号通路分析
  • 批准号:
    19591115
  • 财政年份:
    2007
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Functional analysis of the molecules modulating the proliferative signals of human myeloma cells by IL-6
IL-6调节人骨髓瘤细胞增殖信号分子的功能分析
  • 批准号:
    12670991
  • 财政年份:
    2000
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Meaning of Conversation in an Age of Social Change. - through Yang Du
社会变革时代对话的意义。
  • 批准号:
    11610018
  • 财政年份:
    1999
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Involvement of CD19 molecules in proliferation of human immature myeloma cells by interleukin-6
CD19分子参与白细胞介素6对人未成熟骨髓瘤细胞增殖的影响
  • 批准号:
    10670952
  • 财政年份:
    1998
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似国自然基金

基于IL-6调控Th17/Treg细胞平衡探究复方青娥丸通过重塑骨免疫微环境治疗绝经后骨质疏松症的作用机制
  • 批准号:
    82374491
  • 批准年份:
    2023
  • 资助金额:
    51 万元
  • 项目类别:
    面上项目
重离子(12C6+)辐射通过IL-6/JAK2/STAT3途径调控NKG2D-Ls和FOXP3双靶点增强NK细胞活性的机制研究
  • 批准号:
    82360583
  • 批准年份:
    2023
  • 资助金额:
    32 万元
  • 项目类别:
    地区科学基金项目
一种新的IL-6负调节机制:QKI通过EDC3-DCP1复合物促进IL6 mRNA“脱帽”降解的作用机制研究
  • 批准号:
    82301967
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
IL-6/MUL1调控STING泛素化抑制肝内胆管癌免疫应答的机制研究及干预新方案探索
  • 批准号:
    82373323
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
IL-6/Nrf2/Fpn1通路介导成纤维细胞铁死亡参与托珠单抗抑制系统性硬化症皮肤纤维化的机制研究
  • 批准号:
    82304632
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

IL-6-Fyn-オートファジー経路は糖尿病関連サルコペニアと糖尿病性腎臓病をつなぐか?
IL-6-Fyn 自噬途径是否将糖尿病相关肌少症和糖尿病肾病联系起来?
  • 批准号:
    24K14719
  • 财政年份:
    2024
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
霊長類モデルを用いた末梢血IL-6産生細胞の特徴と免疫記憶に与える影響の解析
灵长类动物模型分析外周血IL-6产生细胞的特性及其对免疫记忆的影响
  • 批准号:
    24K10153
  • 财政年份:
    2024
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
肺移植前に行う体外肺還流中の抗IL-6受容体モノクロナール抗体による肺障害修復
抗IL-6受体单克隆抗体修复肺移植前体外肺灌注过程中的肺损伤
  • 批准号:
    23K27686
  • 财政年份:
    2024
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
心筋炎におけるIL-6の治療標的としての可能性の検討
IL-6作为心肌炎治疗靶点的可能性研究
  • 批准号:
    20K22765
  • 财政年份:
    2023
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Therapeutic approach to confer an anti-tumorigenic role of IL-6 to the pro-tumorigenic cytokine in effector T cells
赋予效应T细胞中促肿瘤细胞因子IL-6抗肿瘤作用的治疗方法
  • 批准号:
    23K06723
  • 财政年份:
    2023
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了